ATE23716T1 - 5,6,7-trinor-4,8-inter-m-phenylen-prostaglandin i2-derivate. - Google Patents

5,6,7-trinor-4,8-inter-m-phenylen-prostaglandin i2-derivate.

Info

Publication number
ATE23716T1
ATE23716T1 AT83100449T AT83100449T ATE23716T1 AT E23716 T1 ATE23716 T1 AT E23716T1 AT 83100449 T AT83100449 T AT 83100449T AT 83100449 T AT83100449 T AT 83100449T AT E23716 T1 ATE23716 T1 AT E23716T1
Authority
AT
Austria
Prior art keywords
carbon atoms
hydrogen
trinor
prostaglandin
phenylene
Prior art date
Application number
AT83100449T
Other languages
German (de)
English (en)
Inventor
Kiyotaka Ohno
Hiroshi Nagase
Kazuhisa Matsumoto
Shintaro Nishio
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11630492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE23716(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Toray Industries filed Critical Toray Industries
Application granted granted Critical
Publication of ATE23716T1 publication Critical patent/ATE23716T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/09Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis
    • C07C29/12Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis of esters of mineral acids
    • C07C29/124Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis of esters of mineral acids of halides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/56Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by isomerisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4015Esters of acyclic unsaturated acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
AT83100449T 1982-01-20 1983-01-19 5,6,7-trinor-4,8-inter-m-phenylen-prostaglandin i2-derivate. ATE23716T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP57006150A JPS58124778A (ja) 1982-01-20 1982-01-20 5,6,7−トリノル−4,8−インタ−m−フエニレンPGI↓2誘導体
EP83100449A EP0084856B2 (en) 1982-01-20 1983-01-19 5,6,7-Trinor-4, 8-inter-m-phenylene prostaglandin I2 derivatives

Publications (1)

Publication Number Publication Date
ATE23716T1 true ATE23716T1 (de) 1986-12-15

Family

ID=11630492

Family Applications (1)

Application Number Title Priority Date Filing Date
AT83100449T ATE23716T1 (de) 1982-01-20 1983-01-19 5,6,7-trinor-4,8-inter-m-phenylen-prostaglandin i2-derivate.

Country Status (8)

Country Link
US (1) US4474802A (enExample)
EP (1) EP0084856B2 (enExample)
JP (1) JPS58124778A (enExample)
AT (1) ATE23716T1 (enExample)
AU (1) AU556348B2 (enExample)
CA (1) CA1226280A (enExample)
DE (1) DE3367774D1 (enExample)
ZA (1) ZA83328B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3765646D1 (de) * 1986-01-24 1990-11-29 Toray Industries 2,5,6,7-tetranor-4,8-inter-m-phenylen-pgi2-derivate.
US4880939A (en) * 1986-12-11 1989-11-14 Toray Industries 2,5,6,7-tetranor-18,18,19,19-tetradehydro-4,8-inter-m-phenylene PGI2 derivatives
AU634213B2 (en) * 1989-02-27 1993-02-18 Toray Industries, Inc. Preparation of 5,6,7-trinor-4,8-inter-m-phenylene pgi2 derivatives
EP0389162B1 (en) * 1989-03-14 1993-12-08 Toray Industries, Inc. 2,5,6,7-Tetranor-4,8-inter-m-phenylene PGI2 derivatives
JP2608135B2 (ja) * 1989-03-31 1997-05-07 科研製薬株式会社 糖尿病性神経障害治療剤
DE4104607A1 (de) * 1991-02-12 1992-08-13 Schering Ag Prostacyclin- und carbacyclinderivate als mittel zur behandlung von fiebrigen erkrankungen
JP3230246B2 (ja) * 1991-04-11 2001-11-19 東レ株式会社 悪性腫瘍転移抑制剤
US5496850A (en) * 1991-04-11 1996-03-05 Toray Industries, Inc. Antimetastasis agent of malignant tumors
US5233059A (en) * 1991-07-25 1993-08-03 Iowa State University Research Foundation, Inc. Synthesis of benzoprostacyclins using palladium catalysis
US5169959A (en) * 1991-09-23 1992-12-08 Iowa State University Research Foundation, Inc. Free radical-catalyzed synthesis of benzoprostacyclins
DE69228235T2 (de) * 1991-10-25 1999-07-01 Toray Industries, Inc., Tokio/Tokyo Verwendung eines Mittels zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankung
JP3102141B2 (ja) * 1992-05-29 2000-10-23 東レ株式会社 養毛育毛剤
DE4226615C1 (de) * 1992-08-07 1994-05-19 Schering Ag Verwendung von Prostan-Derivaten zur Behandlung von chronischer Polyarthritis
EP0686036B1 (de) * 1992-08-07 1997-03-12 Schering Aktiengesellschaft Verwendung von prostanderivaten zur herstellung eines arzneimittels zur behandlung der chronischen polyarthritis
EP0621273B1 (en) * 1992-09-18 1998-12-09 Toray Industries, Inc. Novel sulfonic acide derivative and medicinal use thereof
JPH07126161A (ja) * 1993-10-29 1995-05-16 Toray Ind Inc 心不全治療剤
JP3541417B2 (ja) * 1994-02-24 2004-07-14 日産化学工業株式会社 フェニル置換ヒドロキシシクロペンテノン類、ペンタノン類及びフェニル置換プロスタグランジンi2類中間体並びにその製造法及び光学分割法
DE69527507T2 (de) * 1994-11-17 2002-11-07 Toray Industries Transdermal absorbierbare zubereitung
CN1127336C (zh) * 1995-02-27 2003-11-12 东丽株式会社 肺性心病治疗剂
CZ168896A3 (en) * 1995-06-27 1997-01-15 Egyt Gyogyszervegyeszeti Gyar Oxaindene derivatives and process for preparing thereof
DE19530884C2 (de) * 1995-08-11 1997-07-31 Schering Ag Verwendung von Prostan-Derivaten sowie deren Kombination mit Antibiotika zur Behandlung von bakteriellen Meningitis
AU734650B2 (en) 1996-05-07 2001-06-21 Toray Industries, Inc. Ophthalmic preparations
CA2237620A1 (en) * 1996-09-17 1998-03-26 Toray Industries, Inc. Platelet function increment agent and therapeutic method for thrombocytopathy
EP0925787A4 (en) * 1997-02-27 1999-12-01 Toray Industries DRUGS TO IMPROVE PULMONARY CIRCULATION
WO1998040073A1 (fr) * 1997-03-13 1998-09-17 Toray Industries, Inc. Medicament pour traiter les lesions vasculaires diabetiques
PT947196E (pt) * 1997-03-14 2009-09-24 Toray Industries Preparação de derivado de prostaglandina i de libertação prolongada
US6653345B2 (en) 1997-09-16 2003-11-25 Toray Industries, Inc. C-C chemokine synthesis inhibitor
US6328979B1 (en) 1997-12-26 2001-12-11 Yamanouchi Pharmaceuticals, Co. Ltd. Sustained release medicinal compositions
JP4019481B2 (ja) 1998-01-23 2007-12-12 ソニー株式会社 情報処理装置および方法、情報処理システム、並びに提供媒体
WO2000009161A1 (fr) * 1998-08-12 2000-02-24 Toray Industries, Inc. Agents qui regulent la production de l'inhibiteur 1 des activateurs du plasminogene
WO2000009135A1 (en) * 1998-08-14 2000-02-24 Toray Industries, Inc. Peridermal cell protecting agents
US20030092760A1 (en) * 2001-03-12 2003-05-15 Toray Industries, Inc. Therapeutic agent for renal failure
HU227157B1 (en) * 2001-07-30 2010-09-28 Chinoin Gyogyszer Es Vegyeszet Production of beraprost ester by selective oxidation
JP3340732B1 (ja) * 2001-10-05 2002-11-05 日本医薬品工業株式会社 シクロペンタベンゾフラン誘導体の製造方法及びその製造原料となる新規化合物
GB0215757D0 (en) * 2002-07-08 2002-08-14 Cascade Biochem Ltd Benzoprostacyclin intermediates methods for their preparation and products derived therefrom
JP4702054B2 (ja) 2003-05-09 2011-06-15 東レ株式会社 増強剤
WO2005000316A1 (ja) * 2003-06-25 2005-01-06 Cardiovascular Institute, Ltd. 性交機能改善用外用製剤
PT1913946E (pt) 2005-07-08 2014-04-28 Toray Industries Agente terapêutico e método de tratamento para melhorar a uremia
JP5424291B2 (ja) * 2006-03-03 2014-02-26 独立行政法人国立循環器病研究センター 骨髄細胞の動員剤および動員方法
US8183286B2 (en) * 2006-11-16 2012-05-22 Gemmus Pharma Inc. EP2 and EP4 agonists as agents for the treatment of influenza a viral infection
MX350011B (es) 2008-08-13 2017-08-22 Actelion Pharmaceuticals Ltd Composiciones terapeuticas que contienen macitentan.
CA2777384A1 (en) 2009-10-14 2011-04-21 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
CA2780683A1 (en) 2009-11-13 2011-05-19 Toray Industries, Inc. Therapeutic or prophylactic combination of a prostaglandin i2 and a thiazolidine for diabetes
ES2717226T3 (es) 2011-06-16 2019-06-19 Lung Biotechnology Inc Método de producción de beraprost
CN103509044A (zh) * 2012-06-21 2014-01-15 上海天伟生物制药有限公司 贝前列素钠中间体及其制备方法
KR102131378B1 (ko) 2012-07-19 2020-07-08 카이맨 케미칼 컴파니 인코포레이티드 Ep4-매개의 질병 및 질환의 치료에 사용하기 위한 ep4 수용체-선택적 효능제로서의 디플루오로락탐 화합물
CN103242274B (zh) * 2013-05-22 2014-11-05 孙威 一种贝前列素钠化合物及其制备方法
CN114404588A (zh) 2013-08-09 2022-04-29 阿德利克斯公司 用于抑制磷酸盐转运的化合物和方法
US9765047B2 (en) 2015-08-12 2017-09-19 United Therapeutics Corporation Process for making beraprost
CN106632372B (zh) * 2016-09-26 2019-04-02 上海北卡医药技术有限公司 一种中间体及其制备方法和用途
RU2019121646A (ru) 2016-12-14 2021-01-15 Респира Терапьютикс, Инк. Способы и композиции для лечения легочной гипертензии и других заболеваний легких
CN107325122B (zh) * 2017-01-06 2020-05-01 常州博海威医药科技股份有限公司 制备贝前列腺素的新中间体及其制备方法
MX2020000999A (es) 2017-07-27 2020-07-22 Allergan Inc Agonistas del receptor de prostacyclin para reducir la grasa corporal.
CN109305986B (zh) * 2018-11-13 2021-02-19 济南康和医药科技有限公司 一种贝前列素钠中间体的合成方法
US10577340B1 (en) * 2018-11-26 2020-03-03 Chirogate International Inc. Beraprost-314d crystals and methods for preparation thereof
CN114340631A (zh) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 用于降低患者的血清磷酸盐的组合
CN110746450A (zh) * 2019-09-17 2020-02-04 济南康和医药科技有限公司 一种贝前列素钠关键中间体的合成方法
CN112569181B (zh) * 2019-09-27 2023-03-21 中国科学院上海高等研究院 一种快速增溶肾上腺素的方法
AU2021220877A1 (en) 2020-02-12 2022-09-01 Cytoagents, Inc. Compositions and methods for treating coronavirus infections
TW202317089A (zh) 2021-06-16 2023-05-01 日商東麗股份有限公司 罹患慢性腎臟病的貓的治療方法
TW202317527A (zh) * 2021-06-28 2023-05-01 日商大內新興化學工業股份有限公司 貝前列素或光學活性物之合成中間物及其製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2734791A1 (de) * 1977-07-29 1979-02-15 Schering Ag Neue prostaglandin-i tief 2 -derivate und verfahren zu ihrer herstellung
JPS5931510B2 (ja) * 1979-09-03 1984-08-02 東レ株式会社 5,6,7−トリノル−4,8−インタ−m−フエニレンPGI↓2誘導体
JPS57144276A (en) * 1981-03-03 1982-09-06 Toray Ind Inc 5,6,7-trinor-4,8-inter-m-phenylene pgi2 derivative

Also Published As

Publication number Publication date
JPH0153672B2 (enExample) 1989-11-15
CA1226280A (en) 1987-09-01
EP0084856B1 (en) 1986-11-20
AU1060983A (en) 1983-07-28
US4474802A (en) 1984-10-02
AU556348B2 (en) 1986-10-30
EP0084856B2 (en) 1994-05-04
JPS58124778A (ja) 1983-07-25
EP0084856A1 (en) 1983-08-03
ZA83328B (en) 1983-10-26
DE3367774D1 (de) 1987-01-08

Similar Documents

Publication Publication Date Title
ATE23716T1 (de) 5,6,7-trinor-4,8-inter-m-phenylen-prostaglandin i2-derivate.
ES527954A1 (es) Un procedimiento para preparar isoxazoles
IL56288A (en) 15-deoxy-16-hydroxy-2-decarboxy-2-hydroxymethylprostaglandin derivatives and their preparation
ES8503667A1 (es) Un procedimiento para la preparacion de nuevos derivados de 2-oxo-imidazolina.
ES8401961A1 (es) Procedimiento para la preparacion de nuevas n-(4-indolil-piperidino-alcohil-bencimidazolonas sustituidas.
ES8304567A1 (es) "un procedimiento para preparar nuevos derivados de la n-dihidrotiazolil-3-quinolein-carboxamida".
ES8800145A1 (es) Un procedimiento para preparar un derivado de semicarbazida
DE3477488D1 (en) Polymethoxybenzyl piperazine derivatives, processes for their preparation and pharmaceutical compositions containing said derivatives
MX9206127A (es) Compuestos de acetileno
JPS5750989A (en) Imidazole compound
IL77124A0 (en) 5-alkyl-1-phenyl-2-piperazinoalkylpyrazolin-3-one compounds,their preparation and pharmaceutical compositions containing them
AU550340B2 (en) Dibenzazepine derivatives
DE3266845D1 (en) Hydrocortisone derivatives, their preparation and their utilization
AU562253B2 (en) Thiazolothienoazepine or pyridiue derivatives
CA1273946C (en) ANTICONVULSANT GAMMA-THIOBUTYROLACTONE DERIVATIVES
ES8200648A2 (es) Procedimiento de preparacion de compuestos opacificantes para radiografia y similares
AU8672582A (en) Benzodioxane substituted imidazolines
ES8401008A1 (es) Procedimiento para la preparacion de derivados de carbaciclina.
DE3264556D1 (en) Sulfimines, their salts and their preparation, and pharmaceutical compositions containing them
JPS52100470A (en) Synthesis of hydantoin derivatives
DE3363575D1 (en) Furyloxazolylacetic acid derivatives, process for preparing same and pharmaceutical compositions containing same
ES8103742A2 (es) Un procedimiento de preparacion de nuevos derivados de 1,3-benzodioxina
IL70103A0 (en) Semicarbazides,their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time